TSMC stock: Q4 revenue beat sets up a Jan. 15 earnings test for Taiwan Semiconductor

TSMC stock: Q4 revenue beat sets up a Jan. 15 earnings test for Taiwan Semiconductor

TAIPEI, Jan 11, 2026, 23:05 (GMT+8) — The market has closed.

  • TSMC’s U.S.-listed shares ended Friday up 1.8%, boosted by the chipmaker’s upbeat fourth-quarter revenue outlook.
  • The company reported a 20.4% jump in December revenue compared to the previous year, pushing its 2025 revenue forecast up by 31.6%.
  • Investors are now eyeing the Jan. 15 results for insights on the 2026 outlook, capital spending, and signals tied to AI-driven demand.

Taiwan Semiconductor Manufacturing Co’s U.S.-listed shares closed Friday up 1.77% at $323.63, the final price before Monday’s open. The jump followed the company’s quarterly revenue report, which beat Wall Street estimates. (StockAnalysis)

TSMC’s quick revenue snapshot carries weight since it’s central to the global chip supply chain. Traders lean on its figures to gauge AI-driven spending, which has stayed robust enough to buoy the sector despite softness in other electronics markets. (Reuters)

Looking ahead, the week throws up some tricky macro signals. Tuesday’s U.S. consumer inflation figures and early earnings from major banks could shift rate outlooks—key for tech and chip stocks with rich valuations. (Investopedia)

TSMC reported a 20.45% jump in fourth-quarter revenue from last year, reaching T$1.046 trillion ($33.11 billion) on Friday. This topped the LSEG SmartEstimate of T$1.036 trillion, which favors analysts with stronger track records. The chipmaker is set to release full results and updated guidance, including capital expenditure plans, on Jan. 15. (Reuters)

TSMC reported December 2025 revenue of roughly NT$335.00 billion, slipping 2.5% from November but rising 20.4% compared to the same month last year. For the full year, January to December 2025, revenue hit NT$3,809.05 billion, marking a 31.6% increase over 2024. (TSMC)

Taiwan’s wider trade figures are heading in the same direction, at least for the moment. The finance ministry reported 2025 exports surged to a record $640.75 billion, driven by robust chip and AI-related demand. However, it also warned of risks stemming from policy shifts and geopolitical tensions. (Reuters)

TSMC chairman and CEO C.C. Wei laid it out plainly: “Everything related [to AI], like front-end and back-end capacity, is very tight,” he told investors, according to the Taipei Times. (Taipei Times)

That said, the situation works both ways. Should AI-related orders become uneven or clients delay shipments, investors might quickly shift their attention back to pricing, margins, and the pace of new capacity additions in the industry. And Taiwan’s geopolitical risk premium remains a constant factor.

TSMC’s next major event hits Jan. 15, when it releases its quarterly earnings. Investors will be zeroed in on the company’s guidance for 2026 revenue and capital spending, keeping an eye on how competitors like Samsung Electronics and Intel are positioned for comparison. (Barrons)

Stock Market Today

  • AstraZeneca shifts U.S. trading to NYSE, eyes China expansion and obesity drug growth
    February 1, 2026, 3:03 PM EST. AstraZeneca will move its U.S. stock trading from Nasdaq to the New York Stock Exchange starting Monday, maintaining its AZN ticker. The switch aims to affect liquidity and spreads for U.S. investors. Shares rose 0.65% in London ahead of full-year results on Feb. 10. The company is investing $15 billion in China by 2030 to expand manufacturing and research, focusing on cell therapy and radioconjugates. AstraZeneca also signed a $1.2 billion partnership with CSPC Pharmaceutical for weight-management drugs, with potential milestones up to $3.5 billion. Industry leaders in obesity drugs like Novo Nordisk and Eli Lilly remain competitive, but AstraZeneca hopes monthly dosing and AI-driven peptide technology will differentiate its pipeline.
Berkshire Hathaway stock slips into Monday: BRK.B holders brace for CPI and bank earnings
Previous Story

Berkshire Hathaway stock slips into Monday: BRK.B holders brace for CPI and bank earnings

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next
Next Story

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Go toTop